BioPharma Dive
1,421 FOLLOWERS
BioPharma Dive is a leading industry publication providing in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing, and M&A to research partnerships.
BioPharma Dive
5h ago
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets ..read more
BioPharma Dive
8h ago
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes ..read more
BioPharma Dive
8h ago
First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue ..read more
BioPharma Dive
8h ago
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30 ..read more
BioPharma Dive
10h ago
In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness ..read more
BioPharma Dive
10h ago
The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will involve the elimination of 150 positions ..read more
BioPharma Dive
14h ago
Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers ..read more
BioPharma Dive
1d ago
Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year ..read more
BioPharma Dive
1d ago
Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise ..read more
BioPharma Dive
1d ago
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder ..read more